PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2009 | 4 | 1 | 138-139
Article title

Hepatocellular carcinoma in Central, Eastern, and Southern Europe. What Future after the SHARP Trial?

Content
Title variants
Languages of publication
EN
Abstracts
Keywords
Publisher
Journal
Year
Volume
4
Issue
1
Pages
138-139
Physical description
Dates
published
1 - 3 - 2009
online
11 - 2 - 2009
References
  • [1] American Cancer Society: Cancer Facts and Figures 2007. Atlanta, Ga: American Cancer Society, 2007
  • [2] International agency for Cancer Research, The GLOBOCAN 2002 database. Available at: http://www-dep.iarc.fr
  • [3] Zhu A.X., Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma, Cancer, 2008, 112, 250–9 http://dx.doi.org/10.1002/cncr.23175[Crossref]
  • [4] Shimoda K., Mori M., Shibuta K., Banner B.F., Barnard G.F., Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma, Int. J. Oncol., 1999, 14, 353–359 [PubMed]
  • [5] Poon R.T., Lau C., Pang R., Ng K.K., Yuen J., Tat Fan S., High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies, Ann. Surg. Oncol., 2007, 14, 1835–1845 http://dx.doi.org/10.1245/s10434-007-9366-z[Crossref]
  • [6] Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al., Sorafenib in advanced hepatocellular carcinoma, N. Engl. J. Med., 2008, 359, 378–90 http://dx.doi.org/10.1056/NEJMoa0708857[Crossref]
  • [7] http://www.clinicaltrial.gov/ct2/search
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-008-0089-8
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.